Clinical trialNCT05289947CompletedPhase 2Interventional

MLC1501 Study Assessing Efficacy in Post STrOke Subjects With mOtor Deficits

SponsorMoleac Pte Ltd.Enrollment303StrokeStroke SequelaeStroke, CardiovascularStroke, CryptogenicStroke, EmbolicStroke, Ischemic+1 more conditions

View the registry record on ClinicalTrials.gov

Summary

The lay summary the sponsor registered on ClinicalTrials.gov.

This is a multi-center, randomized, double-blind, placebo-controlled trial of MLC1501 in patients with stroke. Eligible participants will be randomized in a 1:1:1 ratio to orally receive MLC1501 high-dose twice a day, MLC1501 low-dose twice a day, or matching placebo for 24 weeks.

clinicaltrials.gov ↗

Investigators

The overall officials registered on this study. Names that resolve to a findmyKOL profile link to it; the rest are shown as registered.

Christopher Chen, BMBCh, MRCP, FAMS, FRCPE
Departments of Pharmacology and Psychological Medicine, National University of Singapore
Principal Investigator
clinicaltrials.gov ↗

A profile link is shown only when the registered name resolves to a person record with a confident, namesake-checked match; ambiguous names stay unlinked.

Sites

11 registered facilities, with the per-site recruitment status where the registry publishes one. ClinicalTrials.gov does not publish per-site enrollment counts.

Philippines

Metro Davao Medical and Research Center
Davao City, Davao Region, Philippines
Quirino Memorial Medical Center
Manila, Manila, Philippines
University of Santo Tomas Hospital
Manila, Manila, Philippines
Baguio General Hospital and Medical Center
Baguio City, Philippines
West Visayas State University Medical Center
Iloilo City, Philippines
Jose R. Reyes Memorial Medical Center
Manila, Philippines
Manila Doctors Hospita
Manila, Philippines

Singapore

Changi General Hospital
Singapore, Singapore, Singapore
National Neuroscience Institute (nni) @ Tan Tock Seng Hospital (ttsh)
Singapore, Singapore, Singapore
Raffles Hospital
Singapore, Singapore
Singapore General Hospital
Singapore, Singapore

Site investigator names are published by ClinicalTrials.gov only while a study recruits, so completed studies list sites without them.

Drugs studied

The drug and biological interventions registered on this study, normalized to their RxNorm ingredient where possible.

MLC1501

Linked drugs open the directory filtered to KOLs working with them.clinicaltrials.gov ↗

Registration & key dates

Registry attributes as recorded on the ClinicalTrials.gov study record.

Start: 21 Jul 2023
Primary completion: 18 Jul 2025
Completion: 18 Jul 2025
Last update posted: 9 Dec 2025
Registered enrollment: 303
Registry id: NCT05289947

clinicaltrials.gov ↗

Source: ClinicalTrials.gov, via the CTTI AACT database, data as of 24 Aug 2026. Registry facts are shown as registered by the study sponsor; findmyKOL does not interpret them.